跳至主要内容
临床试验/PER-011-20
PER-011-20暂停未知

HYDROXYCHLOROQUINE TO PREVENT SARS-COV-2 INFECTION AMONG HEALTHCARE WORKERS: RANDOMIZED CONTROLLED, OPEN-LABEL, PHASE 3 CLINICAL TRIA

IVERSIDAD PERUANA CAYETANO HEREDIA,0 个研究点目标入组 42 人开始时间: 2020年5月14日最近更新:

试验速览

阶段
未知
状态
暂停
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • A.Healthcare workers in service during the COVID-19 outbreak including medical, nurse, technical and auxiliary staff.
  • B.Negative rapid serologic and molecular testing for SARS-CoV-2.
  • C.Written informed consent.

排除标准

  • A.Presents COVID-19 symptoms including cough, fever, myalgias, headaches, loss of smell and taste
  • B.Prior (last 30 days) or current (or planned use during the study period) use of hydroxychloroquine, chloroquine sulfate or azithromycin.
  • C.Known history of prolonged QT syndrome.
  • D.Known allergy or intolerance to hydroxychloroquine.
  • E.Use of concomitant medications that are contraindicated with the use of hydroxychloroquine.
  • F.Participation might not be beneficial, by investigator judgement.

研究者

发起方
IVERSIDAD PERUANA CAYETANO HEREDIA,

相似试验

HYDROXYCHLOROQUINE TO PREVENT SARS-COV-2 INFECTIO | 临床试验